Practice
Featured experience
Bristol Myers Squibb $13 billion notes offering
The investment-grade offering comprised nine tranches
Cisco Systems $13.5 billion notes offering
The investment-grade offering comprises seven tranches of notes
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Novartis $3.7 billion notes offering
We advised Novartis on the investment-grade debt offering
PPG €900 million notes offering
The investment-grade notes are due 2032
General Motors Financial $2.25 billion senior notes offering
The investment-grade notes are due 2028 and 2032
Leidos $1 billion notes offering and tender offer
We advised Leidos in connection with the transactions
Emerson €1 billion and $500 million notes offering
The investment-grade debt consists of three tranches of notes
MIXUE HK$3.45 billion IPO
We advised MIXUE on its IPO and HKEX listing
CoreWeave acquisition of Weights and Biases
We are advising CoreWeave on the transaction
NatWest Group £750 million contingent convertible additional Tier 1 notes
We advised NatWest Group on the SEC-registered offering
Recursion Pharmaceuticals $500 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
CCC Intelligent Solutions Holdings $433.7 million secondary offering
The shares are listed on the Nasdaq Global Select Market
Rokt $404.2 million secondary transaction
We advised Rokt on the secondary transaction